Cell therapy (CAR-T) · Kills target cells, directed at interleukin-3 receptor alpha chain (CD123) (IL3RA) · developed by Cellectis
UCART123 is an allogeneic, off-the-shelf T-lymphocyte product engineered with TALEN gene editing to express a chimeric antigen receptor targeting CD123 (IL3RA). The CAR-expressing cells bind CD123-expressing cells and cause their lysis, and the endogenous T-cell receptor is removed to reduce the risk of graft-versus-host disease. It is studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04106076 | Phase 1 | Acute Myeloid Leukaemia | Withdrawn | CLLS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukaemia
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLLS page.
See CLLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLLS catalysts and pipeline →